Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PNP | P00491 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyadenosine SCHEMBL193181 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222478 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL593935 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222447 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5982298 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL23982174 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5982291 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19506291 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL21637036 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19877 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605713-B1 | Contacting D-nucleic acids with a racemic mixture of the target molecule and allow for binding; producing L-nucleic acids; in vitro selection of DNA/RNA with high binding affinity and stability | FURSTE JENS PETER (DE) | 2003-08-12 | — | — | US | claimed |
| EP-1292313-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2003-03-19 | — | — | EP | claimed |
| WO-2001091737-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-06 | — | — | WO | claimed |
| WO-2025072834-A2 | METHOD OF SEQUENCING AND SYNTHESIZING L-POLYNUCLEOTIDE | DXOME CO., LTD. (KR) | 2025-04-03 | — | — | WO | disclosed |
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | NOVADEX PHARMACEUTICALS AB (SE) | 2012-12-06 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-0788364-A4 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | UNIV EMORY (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0788364-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0731808-A4 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5599796-A | USING BORON CLUSTER-CONTAINING NUCLEOSIDES OR OLIGONUCLEOTIDES; PARTICULARLY EFFECTIVE FOR BLADDER, PROSTATE AND KIDNEY | EMORY UNIVERSITY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0731808-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996014073-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1996-05-17 | — | — | WO | disclosed |
| EP-0691981-A1 | TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-17 | — | — | EP | disclosed |
| WO-1995015333-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
| WO-1994020523-A1 | TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309705-A1 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES | ENTPD5, MTAP, SLC29A1 | HIF1A 1656/4885SMN1; SMN2 3178/4885PNP 4/4885 |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | HIF1A 3597/4885SMN1; SMN2 3673/4885PNP 1/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | HIF1A 3597/4885SMN1; SMN2 3673/4885PNP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.